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Abstract
The classical somatic mutation theory (SMT) of carcinogenesis and metastasis postulates that malignant transformation
occurs in cells that accumulate a sufficient amount of mutations in the appropriate oncogenes and/or tumor suppressor
genes. These mutations result in cell-autonomous activation of the mutated cell and a growth advantage relative to
neighboring cells. However, the SMT cannot completely explain many characteristics of carcinomas. Contrary to the cell-
centered view of the SMT with respect to carcinogenesis, recent research has revealed evidence that the tumor
microenvironment plays a role in carcinogenesis as well. In this review, we present a new model that accommodates the
role of the tumor microenvironment in carcinogenesis and complements the classical SMT. Our ‘‘feedback’’ model
emphasizes the role of an altered spatiotemporal communication between epithelial and stromal cells during
carcinogenesis: a dysfunctional intracellular signaling in tumorigenic epithelial cells leads to inappropriate cellular
responses to stimuli from associated stromal or inflammatory cells. Thus, a positive feedback loop of the information flow
between parenchymal and stromal cells results. This constant communication between the stromal cells and the tumor cells
causes a perpetually activated state of tumor cells analogous to resonance disaster.
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Introduction
Current Concepts on Carcinogenesis
One of the current prevailing theories of carcinogenesis is the
somatic mutation theory (SMT) of carcinogenesis and metastasis,
which postulates that cancer is a disease based on the trans-
formation of individual cells. SMT proposes that mutations in
tumor suppressor genes and oncogenes lead to the uncontrolled
proliferation of tumor cells in a cell-autonomous fashion. Tumors
progress to more malignant stages of disease by further accumu-
lating mutations in a multistep process [1,2]. In the SMT, cells of
the tumor microenvironment play a simple, subservient role to
that of the original mutated cell (Figure 1) [3].
SMT has been criticized because the accumulation of the three
to six mutations that are necessary for a cell to become malignant
might not be possible in the normal life span of a single cell [2,4,5].
Another very important criticism of SMT is that the malignant
phenotype of epithelial cancer cells seems to be reversible. Several
studies have shown that isolated parenchymal cells from neoplastic
tissues lose their tumorigenic phenotype when transplanted into
normal tissues [6,7,8].
Carcinomas are heterogeneous and structurally complex
tumors, and more credence has recently been given to additional
cell types that contribute to the carcinogenesis and pathophysio-
logical properties of tumors [9,10,11,12]. This perception has led
to newer, tissue-based theories of carcinogenesis [7,9], which
postulate that transformed cells are not autonomous but can be
affected by reciprocal interaction between the parenchymal and
stromal cells [7] (Figure 1).
A study published by Bissell et al. showed that cancer could be
considered as a breakdown in communication between the
epithelium and the surrounding stroma. Transformed cells could
send inappropriate signals to stromal cells that could lead to
aberrant responses that facilitate tumorigenesis. Defects in tumor-
stroma paracrine signaling lead to increasingly aberrant cellular
behavior and ultimately result in increased cellular complexity and
heterozygosity. Likewise, alterations in intercellular communica-
tion could precede and cause the development of carcinomas
because chronic exposure to DNA-damaging agents induces
malignant transformation [9]. According to the results from
a study performed by Axelrod et al., interactions between tumor cells
and stromal cells could be necessary for carcinogenesis. This study
indicated that subclones within a tumor require an extended
period of time to accumulate a tumorigenic complement of
mutations. During this the process of transformation, tumor cells
could depend on stromal interactions for support and growth [13].
Therefore, tissue-based theories question the autonomy of
mutations in epithelial cells and the sovereignty of tumor cells in
acquiring a cancerous phenotype. In this review, we present the
feedback model (FBM) as a novel tissue-based model. The FBM is
based on the assumption that certain mutations do not drive
proliferation and activation in cancer cells in a cell-autonomous
process, but rather in a cell-heteronomous fashion by passively
enabling the deregulation of intracellular signaling processes
within tumor cells. Dysfunctional intracellular signaling leads to
an aberrant response to extracellular stimuli resulting in a positive
feedback loop in the information flow between tumor cells and
stromal cells. Feedback between the tumor and the stroma could
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micromilieu.
In contrast to the SMT, our feedback model postulates a cell-
heteronomous action of certain mutations in the malignant
transformation of epithelial cells. In the FBM, malignant trans-
formation is dependent on inflammatory changes in the tumor-
stroma micromilieu. The FBM is a tissue-based model of
carcinogenesis because it assumes that communication between
stromal cells and tumor cells is important for tumorigenesis.
However, the FBM is unique from typical tissue-based models
because the FBM assumes that different interactions between
different cell types result in a positive feedback loop to encourage
tumor growth.
To illustrate the FBM, we will use pancreatic ductal adenocar-
cinoma (PDAC) as an example. One of the main goals of this
review is to argue that the FBM is completely consistent with the
current body of cancer research. This review will also explore the
implications of the FBM on the different pathophysiological
features of carcinomas.
Results
Feedback of Intercellular Signaling: Basic Assumptions
Stromal cells and their secreted products influence adjacent
epithelial cells through transient signaling to elicit specific cellular
reactions in the target cells. Physiologically, the effects in the target
cells reciprocally produce stimuli for neighboring cells [14].
All signals from the environment are integrated by the intrinsic
cellular information processing mechanism, which has three
important functions: (i) to transfer and magnify extracellular
stimuli to induce cellular response (vertical processing), (ii) to
integrate different extrinsic and intrinsic stimuli and relay the
signal to other cells (horizontal processing) and (iii) to timely
restrict the cellular answer.
Vertical signal processing occurs by receptor internalization,
signal enhancement by adaptor proteins and positive or negative
feedback. Horizontal signal processing is achieved by branching
from signal integration nodes thereby interconnecting different
signaling pathways. The time course of the cellular response to
stimuli is determined by positive and negative feedback loops
within the signaling pathways [15]. In biological systems, negative
Figure 1. Different theories of carcinogenesis. The SMT postulates that mutations in oncogenes lead to cell-autonomous growth. Additional
mutations are necessary for invasive growth (A). The tissue-based models assume that reciprocal communication between tumor and stromal cells
can influence the phenotype of the tumor cells. The tissue-based models question the autonomy of the mutations in epithelial cells and the
sovereignty of the tumor cells in determining the cancer phenotype (B). In the FBM, mutations in genes could show a normal phenotype under
physiological conditions but can be activated by inflammation. Under inflammatory conditions, tumor and stromal cells interact to form a positive
feedback loop. Additional stromal and inflammatory cells become attracted to the inflammatory micromilieu (C).
doi:10.1371/journal.pone.0036719.g001
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Negative feedback allows each cellular reaction to be terminated
when sufficient response or product is produced providing a way
for the cell to control signaling pathways and target gene
expression [15]. The mechanisms by which signaling pathways
are regulated are genetically encoded. Therefore, in the absence of
mutations or disorders in the activation of regulatory genes, cells
should not respond aberrantly to stimuli from neighboring cells.
The FBM assumes that mutations in genes involved in
intracellular signal processing could hinder the ability of the cell
to accurately respond to external stimuli. This could result in
a dysfunction in the finely tuned intercommunication between
cells. Mutations in genes such as these could lead to a dispropor-
tionately high level of activation of the respective signaling
pathways, paradoxical activation or inactivation of signaling
pathways or prolonged activation of certain signaling pathways.
Mutations in proteins involved in signal processing could
theoretically manifest as a normal phenotype under physiological
conditions. However, during inflammatory or regenerative pro-
cesses, several different cell types secrete many different signaling
molecules into the extracellular compartment. Confronted with an
abundance of signaling molecules that may or may not be
antagonistic, epithelial cells must rely on their own ability to
appropriately process intracellular signals to adjust to the situation.
Considering the three main functions of the intracellular signal
processing machinery, disproportionately high activation of in-
flammatory pathways of epithelial cells could result in the
recruitment of additional inflammatory cells to the vicinity of the
epithelial cells enhancing the inflammatory environment. Further-
more, paradoxical activation or inactivation of signaling pathways
in the context of acute inflammation could elicit paradoxical
reactions in neighboring stromal cells as well. Finally, the inability
of epithelial cells to deactivate signaling pathways could also lead
to a prolonged inflammatory micromilieu. The culmination of
these dysfunctions could result in a sustained inflammatory
environment or could induce the proliferation of epithelial cells.
Under these circumstances, the stromal cells would continually
become activated by the inflammatory environment forming
a positive feedback loop of intercellular signaling.
Prerequisites for the Feedback Loop Model
For a feedback loop in the communication between stromal cells
and tumor cells to exist, two prerequisites are necessary: the
existence of a permissive extracellular milieu and mutations in the
corresponding intracellular signaling pathway in the epithelial cell.
The appropriate mutation within the signaling pathway should
occur in a component that is localized at an important node of the
signal-processing pathway. There are numerous genes that fit this
description, and we will refer to these genes as ‘‘loop genes’’. A key
requirement of the feedback loop model is that the stimuli found in
the micromilieu must suit the intracellular defect. This is
analogous to the mechanical principle of resonance disaster
whereby a certain wave frequency can cause a resonance disaster
only when it matches the resonance frequency of the system.
Under physiological conditions within the micromilieu, the
mutation in the loop gene could be silent and confer a normal
phenotype on the cell. However, once the positive feedback loop is
initiated, secreted signaling factors can carry the information to
neighboring epithelial cells resulting in an expansion of the
feedback system. The FBM is consistent with the SMT because
some oncogenes and tumor suppressor genes have pleiotropic
functions, which, in addition to their classical role in cellular
signaling, might act as loop genes.
Example of the Feedback Loop Model in Pancreatic
Cancer
In pancreatic cancer, KRAS mutations and NF-kB activation is
observed in almost all cases [16,17,18,19]. KRAS is a member of
the small GTPase superfamily and is involved in many signal
transduction pathways especially growth signaling pathways [20].
Although KRAS mutations tend to activate the signal transduction
pathways, not all KRAS mutations result in cancer formation. Up
to 39% of individuals without cancer were shown to carry
mutations in this gene [21].
The NF-kB signaling pathway induces the expression of a large
number of genes that have important functions in the regulation of
immune and inflammatory responses including cytokines, chemo-
kines, adhesion molecules and other immunoregulatory proteins.
Additionally, canonical NF-kB controls the expression of proteins
involved in proliferation [22,23].
Physiologically, the proper regulation of NF-kB activation at
epithelial interfaces is crucial for the maintenance of physiological
tissue homeostasis. In inflamed pancreatic tissue, macrophages
and other immune cells significantly stimulate NF-kB and cytokine
expression in parenchymal cells [24,25,26,27].
Normally, the activation of NF-kB in parenchymal cells is
controlled by different negative feedback factors such as the
deubiquitinating enzymes A20 and SOCS [28,29]. If intact during
the inflammatory conditions of the tumor micromilieu, these
negative feedback factors should control the activation of epithelial
cells in the vicinity.
However, KRAS has different interconnections with the NF-kB
signaling such as the MAPK and Akt pathways (Figure 2)
[30,31,32,33]. In pancreatic cancer, interconnections between
KRAS and the NF-kB signaling pathway have been previously
described [34]. Activation of the NF-kB pathway by inflammatory
conditions within the micromilieu could be enhanced by the prior
activating KRAS mutations because KRAS mutation compro-
mises the negative feedback mechanism of A20 and SOCS within
the NF-kB pathway.
In this manner, the augmented activation of NF-kB and KRAS
could largely potentiate the proliferative/inflammatory cellular
response thereby prolonging the inflammatory state of the
micromilieu. This could result in augmented cell division of the
epithelial cells as well as the recruitment of macrophages and other
mesenchymal cells to the microenvironment by inflammatory
mediators forming a feedback of intracellular signaling. Therefore,
KRAS could represent a loop gene.
Discussion
Similarities and Differences of the FBM to the Somatic
Mutation Theory of Carcinogenesis and Metastasis
SMT considers cancer as a cumulative process of genetic
instability and natural selection that ultimately leads to the
malignant transformation of the cell [35]. Once transformed, the
cell displays cell-autonomous growth. In this model, activation of
the cell is static and irreversible (Figure 1). However, most of the
identified mutations associated with cancer were found in fully
developed tumors and thus might not explain the events that
initiate carcinogenesis [7,36].
The FBM suggests that the mutated genes could function in
a different capacity than the classical oncogenes and tumor
suppressor genes. The FBM suggests that intracellular mutations
might act in a cell-heteronomous fashion. By supporting the
communication between different cell types of the tumor, the
mutations could lead to a perpetual inflammatory and/or
proliferative micromilieu. Indeed, there could exist an overlap
Feedback Loop Model
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putative loop genes because some of the classical genes could also
initiate a feedback loop. Similarly to SMT, the FBM expects the
occurrence of additional mutations because of the large number of
proliferating cells within the tumor. In in vitro cell cultures, the
accumulation of mutations could explain the fact that most tumor
cell lines in culture can initially only grow in the presence of large
amounts of growth factors and other hormones that mimic an
inflammatory micromilieu [37]. However, some tumor cell lines
can be adapted to growth in reduced serum or serum-free
conditions [38]. Additional mutations could provide an autocrine
feedback loop thereby rendering the cell lines independent from
stromal cell support.
Similarities and Differences of the FBM to the Tissue-
based Models
The tumor stroma seems to have an important influence on
carcinogenesis [6]. Tissue-based models of carcinogenesis postu-
late that the micromilieu and microarchitecture can modulate the
tumor phenotype (Figure 1). Previous studies have provided
examples for different conditions under which the stroma can
Figure 2. Normal activation of NF-kB and KRAS in an inflammatory environment. Negative feedback loop within the NF-kB pathway by
SOCS and A20 counteracts the activated state of the epithelial cell (A). The non-physiological activation of KRAS impairs the negative feedback loop
within the NF-kB pathway and leads to a perpetual inflammatory microenvironment (B).
doi:10.1371/journal.pone.0036719.g002
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mutations and, therefore, the pathophysiology of the tumor
[6,39]. Tissue-based models question the dominance of the
mutations in epithelial cells and the sovereignty of the tumor cells
in determining the cancer phenotype. However, previous tissue-
based models have proposed that malignant transformation is
gained according to the SMT, and the molecular mechanisms,
such as those that recruit stromal cells to the vicinity of the tumor
in tissue-based models, are cell-autonomous according to the SMT
[6]. As mentioned above, the FBM suggests a cell-heteronomous
role for cellular mutations because the function of mutations in
loop genes is passive, and the promotion of carcinogenesis by the
appropriate tumor microenvironment is necessary. The FBM is
also a tissue-based model of carcinogenesis because it assumes that
the communication between stromal cells and tumor cells is
important for tumorigenesis. However, the FBM is unique from
typical tissue-based models because the FBM postulates that the
interaction between the different cell types results in a positive
feedback loop. Under the FBM, reciprocal activation of the tumor
cell and the tumor microenvironment is required for malignant
transformation. In the following sections, we will discuss the
implications of our FBM on the different pathophysiological
features of solid tumors.
Implications of the Feedback Model on the Relationship
Between Inflammation and Cancer
Many cancers are thought to originate from chronic in-
flammatory environments [40,41]. Persistent infections with
Helicobacter pylori cause both gastric cancer and gastric lymphoma.
Similarly, hepatitis C infections are strongly associated with
hepatocellular carcinomas, and schistosomiasis is a major cause of
bladder cancer [12]. The influence of inflammation on carcino-
genesis in PDAC has been studied by Guerra et al., who used
a mouse model of pancreatic cancer. This study revealed that in
adult mice that expressed an exocrine cell-specific somatic KRAS
mutation, PanIN lesions and invasive pancreatic cancer did not
develop unless chronic pancreatitis was induced [42]. Interesting-
ly, treatment of other mouse models of pancreatic cancer, namely
KPC-mice, with anti-inflammatory drugs prolonged the time until
the development of tumors [43]. Although KRAS mutations are
frequently observed in patients with chronic pancreatitis [44,45],
not every patient with pancreatitis and KRAS mutations develop
pancreatic cancer [46]. As postulated above, not every in-
flammatory microenvironment must inevitably result in a feedback
loop even if epithelial cells harbor a mutation in a loop gene.
Implication on the Tumor Microarchitecture
SMT proposes that cancer cells can proliferate in an unlimited
fashion; therefore, one would expect an anarchical distribution of
epithelial cells within the tumor. Contrary to this, various solid
tumors display defined microarchitectures. The microarchitecture
of pancreatic cancer is comparable to chronic pancreatitis
[14,47,48], which could be explained by the composition of the
tumor micromilieu: in our model the tumor microenvironment has
a great significance because it comprises the soluble factors that
allow the information flow between tumor cells and stromal cells.
These factors are comparable to those present during chronic
inflammation and are strong chemoattractants for different cell
types such as fibroblasts [49]. Indeed, activated pancreatic stellate
cells appear to be the most important component of the tumor
microenvironment in pancreatic cancer and chronic pancreatitis
[48,50,51]. However, macrophages and mast cells tend to closely
associate with the parenchymal cells as well [24,25].
Because the signaling molecules involved in the information
flow in the FBM are extracellular and soluble, the size of the tumor
is important. In very small tumors, the soluble factors within the
ECM might easily be affected by changes in the neighboring
micromilieu. This change could modify the information flow
within the tumor resulting in the termination of the feedback field.
After a critical mass of cells becomes adapted to the positive
feedback field in larger tumors, the feedback process might be
stable enough to be insensitive to changes in the surrounding
tissues. The importance of the microenvironment could also
explain tumor dormancy, i.e., the variable period of time during
which tumor cells exist in a non-proliferative state. Many tumors
recur several years after treatment [52]. A previous study has
shown that tumor cells are capable of existing as single cell for
a prolonged period of time in some organs [53]. Perhaps these
dormant tumor cells can be reactivated by a change e.g., in the
local microenvironment to one that is inflammatory or otherwise
pathological.
Implications of the Feedback Model on Infiltrative
Growth and Metastasis
The capacity of cancer cells to successfully invade and
metastasize is dependent on the ability of cancer cells to migrate
and to penetrate the ECM. Both of these characteristics are
thought to result from the accumulation of additional mutations in
other genes [54]. However, several lines of evidence suggest that
such mutations are not necessary for metastatic capability. First,
migration is accomplished by the downregulation of cell adhesion
molecules and the upregulation of cell mobility molecules. The
process of acquiring cell migration markers is called epithelial-
mesenchymal transition (EMT). EMT is found in cells in different
acute and chronic inflammatory conditions [14,55,56]. Invasion of
epithelial cells in wound healing shows similarities to malignant
tumor progression [57]. Therefore, tumor cells may not need to
activate EMT by cellular mutations, but EMT could be triggered
by the inflammatory microenvironment. Second, infiltration of
tumor cells into the extracellular matrix (ECM) is not necessarily
dependent on mutations. The intuitive assumption that proteases
are produced by the tumor cells has been challenged by the finding
that most proteases are derived from stromal cells [58,59]. Tumor
cells might even lack the capacity to actively invade tissue. An
electron microscopy study showed that tumor cell invasion into the
peritoneum only occurred where the mesothelial cells were
damaged and where there was inflammation of the underlying
stroma [60].
Implications of the Feedback Model on Localization of
Metastases
To date, the seed-and-soil theory of Paget [61] and the
mechanistic theory of Ewing [62] are commonly used to explain
the localization of metastases. Compared to the large amount of
cells in a typical primary carcinoma, metastasis is a rare event.
However, the evaluation of the outcomes of patients with
peritoneo-venous shunts for malignant ascites showed that millions
of viable tumor cells could be detected in the jugular vein, even
though the risk of metastasis was not significantly increased [63].
Among other important molecular mechanisms [59], the
assumption of the existence of a positive feedback loop could
predict the localization metastases. Cells of the immune system,
hormones and cytokines are an integrative part of the tumor
microenvironment in the FBM. These components are drained
locally by efferent venous circulation or lymphatic vessels [64].
According to our model, primary tumor cells are dependent on
Feedback Loop Model
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are separated from the primary tumor will preferentially grow in
organs to which the components of the feedback field drain or
where inflammatory cells derived from the feedback field localize.
Indeed, pancreatic cancer metastasizes preferentially to the lymph
nodes and liver [65]. As the burden of tumor cells will eventually
grow, the factors of the tumor microenvironment could be
traceable within the circulatory system of the patient leading to
the development of local and distant metastases.
Role of Cancer Stem Cells in the FBM
In organs and tissues, normal stem cells reside at the apex of the
hierarchal scheme that drives organogenesis. The realization that
tumors themselves function as complex organs initiated the
concept that cancer cells with the properties of stem cells may
be the key drivers of tumorigenesis. This theory has been denoted
the cancer stem cell theory [66,67], which proposes that cancer
stem cells arise from genetic mutations amassed by normal adult
stem cells. Cancer stem cells in pancreatic cancer are defined by
the markers CD44, CD24, ESA and CD133. Pancreatic cancer
stem cells are further defined by their potency for tumor formation
in vitro and in vivo [67]. The cancer stem cell theory explains many
shortcomings of the SMT. For example, cancer stem cells can
survive long enough to accumulate the mutations necessary for
malignant transformation [66,67]. However, the existence of stem
cells would not contradict the FBM because stem cells as well as
epithelial cells can initiate a feedback loop based on cell signaling
aberrancy.
Possible Models for Investigating the FBM
Models that can directly investigate tissue-based concepts of
carcinogenesis are difficult to devise because of the complex nature
of these models. Animal models appear to be the most appropriate
type of model available for this purpose. Recently, an animal
model that selectively expresses endogenous KRAS (G12V)
oncogene in centroacinar lineage cells was designed. This mouse
could serve as a good model to investigate the effects of different
inflammatory conditions on carcinogenesis [42]. Cell lines derived
from this mouse model could be used to analyze the effect of co-
culture with different cell types on untransformed cells in vitro. Still,
the investigation of the FBM is limited by the difficulty in
analyzing processes involved in early carcinogenesis in humans.
Isolation of cell lines from human pancreatic carcinomas with
explant culture techniques showed that an initial outgrowth of
tumor cells occurred in 51.8% of the tumor samples. However,
most of the cell lines senesced, and only 9.25% of the cell lines
were capable of being perpetually propagated [68]. These results
suggest that the permanent cell lines represent advanced tumors
that might have accumulated sufficient mutations to grow in vitro.
Most permanent cell lines will therefore not represent early stages
of carcinogenesis and are not suitable for investigating the FBM.
Therapeutic Consequences of the Theory
The efficacy of targeting the tumor microenvironment can be
found in recent therapeutic strategies for hepatocellular carcino-
ma. This cancer type is accompanied by a fibrotic stromal reaction
consisting of hepatic stellate cells, a physiological response often
found in tumor tissues. Recent clinical studies have indicated that
chemotherapy for hepatocellular carcinoma could be more
effective if therapies targeting the underlying liver fibrosis were
also employed [69].
This phenomenon was also shown in pancreatic cancer as well.
An experimental approach to reduce fibrosis and, therefore, the
inflammatory microenvironment in a mouse model of pancreatic
cancer (KPC-mouse) largely enhanced the response towards
chemotherapy [70]. Inflammation can also be targeted to reduce
the incidence of cancer. Studies on the chemoprevention of cancer
showed that chronic suppression of inflammation through the use
of non-steroidal anti-inflammatory drugs resulted in a lower
incidence of colon and breast cancer [6,71].
In conclusion, the FBM is unique among the tissue-based
models because, in the FBM, the tumor and stromal cells interact
to form a positive feedback loop. The result is the perpetuation of
an inflammatory/proliferative state of cellular activation. The
FBM further postulates that loop genes act in a cell-heteronomous
fashion. However, the FBM is thought to supplement, not to
supplant the SMT. The present review demonstrates that such
a feedback loop is possible, and the FBM model corresponds to
many of the characteristics of tumor growth and tumor
pathophysiology.
Materials and Methods
Literature Search
The protein interactions for Figure 2 were assembled from
electronic databases, such as the Kyoto Encyclopedia of Genes
and Genomes (www.genome.ad.jp/kegg), Gene Data Base of the
National Center for Biotechnology Information (www.ncbi.nlm.
nih.gov) and GeneMAPP (www.genmapp.org). For literature
search we used PubMed (www.ncbi.nlm.nih.gov/pubmed) and
Google Scholar (scholar.google.de).
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